Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
11 Results for "
CGRP release
" in MedChemExpress (MCE) Product Catalog:
Products (11)
11 Results for "CGRP release" in MCE Product Catalog:
6
Dihydroergotamine mesylate is a blood-brain barrier-permeable semi-synthetic ergot alkaloid, acting as a full agonist of 5-HT1B/1D receptors (Ki values of 0.3 nM and 2.5 nM, respectively; functional IC50 values of 2 nM and 2.2 nM, respectively). Dihydroergotamine mesylate inhibits Forskolin (HY-15371)-stimulated cAMP accumulation, possesses α-adrenergic receptor antagonistic activity and weak dopaminergic agonistic activity. It mediates intracranial cerebrovascular contraction, inhibits the release of neuropeptides such as CGRP/substance P, and suppresses neurogenic inflammation by activating 5-HT1B/1D receptors in the trigeminovascular system. Dihydroergotamine mesylate binds to the catalytic site of Trypanosoma cruzi trypanothione reductase and exhibits trypanocidal activity in vitro. Dihydroergotamine mesylate can be used in studies related to migraine and trypanosome infections .
1
1 Cited Publications
Cat. No.: HY-P1080
CAS No.: 145017-83-0
Target:
Research Areas:
1
1 Cited Publications
Cat. No.: HY-P1080A
Target:
Research Areas:
Cat. No.: HY-P5226
CAS No.: 936544-53-5
Research Areas:
Palmitoyl tripeptide-8 is an immunomodulatory peptide and neurotransmitter inhibitory peptide. Palmitoyl tripeptide-8 inhibits the activation of the NF-κB pathway and the production of pro-inflammatory cytokines (IL-8, IL-6, and TNF-α). Palmitoyl tripeptide-8 activates the cutaneous opioid system and reduces CGRP release. Palmitoyl tripeptide-8 decreases the number of dilated capillaries, the size of dilated vessels, and the degree of edema in skin explants treated with Substance P (HY-P0201). Palmitoyl tripeptide-8 is used as an active ingredient in cosmetics for sensitive skin. Palmitoyl tripeptide-8 is utilized in research related to sensitive skin .
Target:
Research Areas:
Dihydroergotamine (DFN-19) is a blood-brain barrier-permeable semi-synthetic ergot alkaloid, acting as a full agonist of 5-HT1B/1D receptors (Ki values of 0.3 nM and 2.5 nM, respectively; functional IC50 values of 2 nM and 2.2 nM, respectively). Dihydroergotamine inhibits Forskolin (HY-15371)-stimulated cAMP accumulation, possesses α-adrenergic receptor antagonistic activity and weak dopaminergic agonistic activity. It mediates intracranial cerebrovascular contraction, inhibits the release of neuropeptides such as CGRP/substance P, and suppresses neurogenic inflammation by activating 5-HT1B/1D receptors in the trigeminovascular system. Dihydroergotamine binds to the catalytic site of Trypanosoma cruzi trypanothione reductase and exhibits trypanocidal activity in vitro. Dihydroergotamine can be used in studies related to migraine and trypanosome infections .
Cat. No.: HY-136820S1
Research Areas:
Magnesium malate is an orally active organic acid-chelated magnesium complex. Magnesium malate promotes the release of prostaglandin E2 (PGE2) from macrophages, synergistically stimulates the synthesis/release of calcitonin gene-related peptide (CGRP) from dorsal root ganglion neurons, and upregulates the osteogenic transcription factor RUNX2 in osteoblasts via the Mg 2+-PGE2-CGRP axis, thereby promoting osteoblast proliferation. Magnesium malate can be incorporated into calcium phosphate bone cement as a modifying component to improve compressive strength, shorten setting time and enhance disintegration resistance. Magnesium malate increases serum magnesium levels. Magnesium malate can be used in studies related to bone defects and magnesium deficiency .
Cat. No.: HY-136820
CAS No.: 38668-01-8
Research Areas:
Taurultam is the major active hydrolytic metabolite of Taurolidine (HY-W011522), which selectively activates hTRPA1 to trigger effects in sensory neurons. Taurultam exhibits activity against SARS-CoV-2 variants, influenza A viruses (H1N1, H3N2) and influenza B viruses. Taurultam induces mild tracheal sensory nerve stimulation and CGRP release in mice. Taurultam can be used in studies related to SARS-CoV-2 infection, influenza virus infection, and co-infection with SARS-CoV-2 and influenza A virus.
Cat. No.: HY-182539
CAS No.: 1202877-06-2
Target:
Research Areas:
Cat. No.: HY-B0670S
Dihydroergotamine-d3 is the d3-labeled Dihydroergotamine (HY-B0670). Dihydroergotamine (DFN-19) is a blood-brain barrier-permeable semi-synthetic ergot alkaloid, acting as a full agonist of 5-HT1B/1D receptors (Ki values of 0.3 nM and 2.5 nM, respectively; functional IC50 values of 2 nM and 2.2 nM, respectively). Dihydroergotamine inhibits Forskolin (HY-15371)-stimulated cAMP accumulation, possesses α-adrenergic receptor antagonistic activity and weak dopaminergic agonistic activity. It mediates intracranial cerebrovascular contraction, inhibits the release of neuropeptides such as CGRP/substance P, and suppresses neurogenic inflammation by activating 5-HT1B/1D receptors in the trigeminovascular system. Dihydroergotamine binds to the catalytic site of Trypanosoma cruzi trypanothione reductase and exhibits trypanocidal activity in vitro. Dihydroergotamine can be used in studies related to migraine and trypanosome infections .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
